Related Experiment Video

Updated: Dec 7, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.9K

Down-Regulation of AHNAK2 Inhibits Cell Proliferation, Migration and Invasion Through Inactivating the MAPK Pathway

Dong-Wei Wang1, Hai-Zheng Zheng2, Na Cha1

  • 1Department of Pathology, Changchun Obstetrics-Gynecology Hospital, Nanguan District, Changchun, Jilin, China.

Technology in Cancer Research & Treatment
|October 1, 2020
PubMed

Insights

AHNAK2 protein is elevated in lung adenocarcinoma, promoting cancer progression by activating the MAPK pathway. Reducing AHNAK2 inhibits tumor growth, migration, and invasion, offering a potential therapeutic target for lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • AHNAK nucleoprotein 2 (AHNAK2) is implicated in neuroblast differentiation and cancer development.
  • The precise role of AHNAK2 in lung adenocarcinoma pathogenesis remains unclear.

Purpose of the Study:

  • To investigate the molecular mechanism and clinical significance of AHNAK2 in lung adenocarcinoma.
  • To explore AHNAK2's role in tumor progression and its association with the MAPK signaling pathway.

Main Methods:

  • Bioinformatic analysis using Oncomine and GEPIA datasets.
  • Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot.
  • In vitro functional assays including CCK-8, wound-healing, transwell, and flow cytometry.
  • Gene knockdown using si-AHNAK2 and pathway inhibition with U0126.

Main Results:

  • AHNAK2 expression is significantly upregulated in lung adenocarcinoma tissues and correlates with poor patient prognosis.
  • AHNAK2 knockdown suppressed cell proliferation, migration, invasion, and induced apoptosis in lung adenocarcinoma cells.
  • AHNAK2 activation of the MAPK pathway (p-MEK, p-ERK, p-P90RSK) was confirmed, with similar effects observed upon MEK inhibition.

Conclusions:

  • AHNAK2 acts as an oncogene in lung adenocarcinoma by promoting cell proliferation, migration, and invasion via MAPK pathway activation.
  • AHNAK2 represents a potential therapeutic target for lung adenocarcinoma treatment.
Keywords:
AHNAK2MAPK pathwaycell behaviorslung adenocarcinomaprognosis

More Related Videos

The Soft Agar Colony Formation Assay08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

113.2K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.0K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K